NZ610826A - Compositons and methods for targeting type 1 interferon producing cells - Google Patents
Compositons and methods for targeting type 1 interferon producing cellsInfo
- Publication number
- NZ610826A NZ610826A NZ610826A NZ61082611A NZ610826A NZ 610826 A NZ610826 A NZ 610826A NZ 610826 A NZ610826 A NZ 610826A NZ 61082611 A NZ61082611 A NZ 61082611A NZ 610826 A NZ610826 A NZ 610826A
- Authority
- NZ
- New Zealand
- Prior art keywords
- immunoglobulin
- compositons
- methods
- producing cells
- binds
- Prior art date
Links
- 210000004544 dc2 Anatomy 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 4
- 102000018358 immunoglobulin Human genes 0.000 abstract 4
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 abstract 2
- 102000010790 Interleukin-3 Receptors Human genes 0.000 abstract 1
- 108010038452 Interleukin-3 Receptors Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 210000003651 basophil Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 231100000167 toxic agent Toxicity 0.000 abstract 1
- 239000003440 toxic substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/707,297 US20100209341A1 (en) | 2009-02-18 | 2010-02-17 | Treatment of chronic inflammatory conditions |
| US37449710P | 2010-08-17 | 2010-08-17 | |
| US37448910P | 2010-08-17 | 2010-08-17 | |
| NZ601760A NZ601760A (en) | 2010-02-17 | 2011-02-17 | Compositions and methods for targeting type 1 interferon producing cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ610826A true NZ610826A (en) | 2015-01-30 |
Family
ID=44482392
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ610826A NZ610826A (en) | 2010-02-17 | 2011-02-17 | Compositons and methods for targeting type 1 interferon producing cells |
| NZ601760A NZ601760A (en) | 2010-02-17 | 2011-02-17 | Compositions and methods for targeting type 1 interferon producing cells |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ601760A NZ601760A (en) | 2010-02-17 | 2011-02-17 | Compositions and methods for targeting type 1 interferon producing cells |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2536430B1 (enExample) |
| JP (1) | JP6018507B2 (enExample) |
| KR (1) | KR101842907B1 (enExample) |
| CN (1) | CN103002913B (enExample) |
| AU (1) | AU2011217728B2 (enExample) |
| CA (1) | CA2789810C (enExample) |
| ES (1) | ES2618562T3 (enExample) |
| IL (1) | IL221504B (enExample) |
| NZ (2) | NZ610826A (enExample) |
| WO (1) | WO2011100786A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100209341A1 (en) | 2009-02-18 | 2010-08-19 | Csl Limited | Treatment of chronic inflammatory conditions |
| EP2839842A1 (en) * | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
| LT3247725T (lt) | 2015-01-23 | 2020-10-12 | Sanofi | Anti-cd3 antikūnai, anti-cd123 antikūnai ir bispecifiniai antikūnai, specifiškai surišantys cd3 ir (arba) cd123 |
| TW201709932A (zh) * | 2015-06-12 | 2017-03-16 | 西雅圖遺傳學公司 | Ｃｄ１２３抗體及其共軛物 |
| CN109715803B (zh) * | 2016-04-25 | 2023-07-07 | 巴塞尔大学 | 等位基因编辑及其应用 |
| MX2021003543A (es) | 2018-09-27 | 2021-06-23 | Xilio Dev Inc | Polipeptidos de citocinas enmascaradas. |
| JP2023553323A (ja) | 2020-11-25 | 2023-12-21 | エクシリオ デベロップメント， インコーポレイテッド | 腫瘍特異的に切断可能なリンカー |
| WO2022144836A1 (en) | 2020-12-31 | 2022-07-07 | Sanofi | Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123 |
| TW202413419A (zh) | 2022-05-27 | 2024-04-01 | 法商賽諾菲公司 | 與ｎｋｐ４６和ｂｃｍａ變體結合之具有ｆｃ工程化的自然殺手（ｎｋ）細胞接合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050013810A1 (en) * | 2001-05-08 | 2005-01-20 | Waller Edmund K | Regulating immune response using dendritic cells |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US7763242B2 (en) * | 2006-09-07 | 2010-07-27 | Scott and White Memorial Hospital | Methods for treating myelodysplastic syndrome with a human interleukin-3-diphtheria toxin conjugate |
| JP2008162954A (ja) * | 2006-12-28 | 2008-07-17 | Kirin Pharma Co Ltd | 形質細胞様樹状細胞特異的膜分子に対する抗体を含む治療剤 |
| WO2008127735A1 (en) * | 2007-04-13 | 2008-10-23 | Stemline Therapeutics, Inc. | Il3ralpha antibody conjugates and uses thereof |
| BRPI0819887A2 (pt) * | 2007-12-06 | 2017-05-23 | Csl Ltd | métodos e agentes para inibição de celulas-tronco leucêmicas, e para o tratamento de uma condição de câncer hematológico em um paciente, e, uso de uma molécula de ligação a antigeno |
| US20100209341A1 (en) * | 2009-02-18 | 2010-08-19 | Csl Limited | Treatment of chronic inflammatory conditions |
-
2011
- 2011-02-17 WO PCT/AU2011/000155 patent/WO2011100786A1/en not_active Ceased
- 2011-02-17 NZ NZ610826A patent/NZ610826A/en unknown
- 2011-02-17 AU AU2011217728A patent/AU2011217728B2/en active Active
- 2011-02-17 EP EP11744183.2A patent/EP2536430B1/en active Active
- 2011-02-17 JP JP2012553146A patent/JP6018507B2/ja active Active
- 2011-02-17 NZ NZ601760A patent/NZ601760A/xx not_active IP Right Cessation
- 2011-02-17 CN CN201180016427.5A patent/CN103002913B/zh active Active
- 2011-02-17 ES ES11744183.2T patent/ES2618562T3/es active Active
- 2011-02-17 KR KR1020127024197A patent/KR101842907B1/ko active Active
- 2011-02-17 CA CA2789810A patent/CA2789810C/en active Active
-
2012
- 2012-08-16 IL IL221504A patent/IL221504B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CN103002913A (zh) | 2013-03-27 |
| JP6018507B2 (ja) | 2016-11-02 |
| WO2011100786A1 (en) | 2011-08-25 |
| CA2789810C (en) | 2020-12-01 |
| KR101842907B1 (ko) | 2018-03-28 |
| AU2011217728B2 (en) | 2013-03-14 |
| EP2536430A4 (en) | 2013-09-04 |
| EP2536430B1 (en) | 2016-12-14 |
| ES2618562T3 (es) | 2017-06-21 |
| CA2789810A1 (en) | 2011-08-25 |
| CN103002913B (zh) | 2015-12-16 |
| AU2011217728A1 (en) | 2012-09-06 |
| NZ601760A (en) | 2013-10-25 |
| JP2013519690A (ja) | 2013-05-30 |
| KR20130004576A (ko) | 2013-01-11 |
| IL221504B (en) | 2019-06-30 |
| EP2536430A1 (en) | 2012-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ610826A (en) | Compositons and methods for targeting type 1 interferon producing cells | |
| MX341119B (es) | Estructuras multiméricas específicas para ligando inductor de apoptosis relacionada con el factor de necrosis tumoral r2 (trail). | |
| NZ586053A (en) | Anti-vegf antibody compositions and methods | |
| WO2013063419A3 (en) | A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting | |
| MX2009004532A (es) | Composiciones y metodos para unir esfingosina-1-fosfato. | |
| MX348578B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
| MY183977A (en) | Cytotoxic benzodiazepine derivatives | |
| MX370565B (es) | Miembros de la familia tnf modificados dirigidos. | |
| WO2010017103A3 (en) | Fully human anti-human nkg2d monoclonal antibodies | |
| NZ721184A (en) | Therapeutic peptides | |
| MX348579B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| NZ607996A (en) | Substituted nucleotide analogs | |
| EP3974453A3 (en) | Agents and methods for treating diseases that correlate with bcma expression | |
| EA201590207A1 (ru) | Композиции и способы регуляции car-т-клеток | |
| EP2604280A3 (en) | Compositions and methods for inhibiting PDGFRBETA and VEGF-A | |
| NZ599737A (en) | Il-17a antagonists | |
| WO2013061098A3 (en) | Functional isotype switching of chimaeric antibody chains & chimaeric animals expressing different igh isotypes | |
| HK1216850A1 (zh) | 抗ntb-a抗體及相關的組合物和方法 | |
| MX2013002048A (es) | Conjugados, particulas, composiciones y metodos relacionados. | |
| NZ612175A (en) | Anti ccr4 antibodies and uses thereof | |
| MX353476B (es) | Anticuerpos anti-cxcl13 y metodos para usarlos. | |
| IN2014CN04648A (enExample) | ||
| MX370721B (es) | Compuestos y composiciones novedosas para atacar las células madre del cáncer. | |
| PH12013502144A1 (en) | Multiple myeloma treatment | |
| HK1200120A1 (en) | Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 17 FEB 2018 BY FB RICE Effective date: 20150512 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 FEB 2019 BY CPA GLOBAL(PATRAFEE) AB Effective date: 20180124 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 FEB 2020 BY CPA GLOBAL(PATRAFEE) AB Effective date: 20190209 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 FEB 2021 BY CPA GLOBAL (PATRAFEE) AB Effective date: 20200117 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 FEB 2022 BY CPA GLOBAL Effective date: 20201231 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 FEB 2023 BY CPA GLOBAL Effective date: 20220107 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 FEB 2024 BY CPA GLOBAL Effective date: 20230112 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 FEB 2025 BY CPA GLOBAL Effective date: 20240104 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 FEB 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20250102 |